Flutamide versus prednisone in patients with prostate Cancer symptomatically progressing after androgen-ablative therapy : A phase III study of the European Organization for Research and Treatment of Cancer genitourinary group
- Author
- FOSSA, S. D; SLEE, P. H. Th; BRAUSI, M; HORENBLAS, S; HALL, R. R; HETHERINGTON, J. W; AARONSON, N; DE PRIJCK, L; COLLETTE, L
Department of Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Oslo, Norway
European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium
Freeman Hospital, Newcastle, United States
Netherlands Cancer Hospital, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
Princess Royal Hospital, Hull, United Kingdom
San Raffaele, Milan, Italy
St Antonius Hospital, Nieuwegein, Netherlands - Source
Journal of clinical oncology. 2001, Vol 19, Num 1, pp 62-71 ; ref : 28 ref
- ISSN
- 0732-183X
- Scientific domain
- Medical oncology
- Publisher
- Lippincott Williams & Wilkins, Baltimore, MD
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Antiandrogène Anticancéreux Antigène spécifique prostate Antihormone Chimiothérapie Composé non stéroïde Corticostéroïde Essai clinique phase III Flutamide Homme Marqueur tumoral Prednisone Prostate Qualité vie Stade avancé Toxicité Traitement Tumeur maligne Voie orale Europe Appareil génital mâle pathologie Appareil urinaire pathologie Prostate pathologie
- Keyword (en)
- Antiandrogen Antineoplastic agent Prostate specific antigen Antihormone Chemotherapy Non steroid compound Corticosteroid Phase III trial Flutamide Human Tumoral marker Prednisone Prostate Quality of life Advanced stage Toxicity Treatment Malignant tumor Oral administration Europe Male genital diseases Urinary system disease Prostate disease
- Keyword (es)
- Antiandrógeno Anticanceroso Antigeno específico prostata Antihormona Quimioterapia Compuesto no esteroide Corticoesteroide Ensayo clínico fase III Flutamida Hombre Marcador tumoral Prednisona Prostata Calidad vida Estadio avanzado Toxicidad Tratamiento Tumor maligno Vía oral Europa Aparato genital macho patología Aparato urinario patología Prostata patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R02 Chemotherapy
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 865304
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1200/JCO.2001.19.1.62 
https://dx.doi.org/10.1200/JCO.2001.19.1.62
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2001.19.1.62\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:226:\"Flutamide versus prednisone in patients with prostate Cancer symptomatically progressing after androgen-ablative therapy : A phase III study of the European Organization for Research and Treatment of Cancer genitourinary group\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"62\";s:8:\"\u0000*\u0000epage\";s:2:\"71\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"FOSSA\";s:10:\"\u0000*\u0000aufirst\";s:4:\"S. D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:14:\"SLEE, P. H. Th\";i:1;s:9:\"BRAUSI, M\";i:2;s:12:\"HORENBLAS, S\";i:3;s:10:\"HALL, R. R\";i:4;s:18:\"HETHERINGTON, J. W\";i:5;s:11:\"AARONSON, N\";i:6;s:12:\"DE PRIJCK, L\";i:7;s:11:\"COLLETTE, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:226:\"Flutamide versus prednisone in patients with prostate Cancer symptomatically progressing after androgen-ablative therapy : A phase III study of the European Organization for Research and Treatment of Cancer genitourinary group\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2001.19.1.62\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:226:\"Flutamide versus prednisone in patients with prostate Cancer symptomatically progressing after androgen-ablative therapy : A phase III study of the European Organization for Research and Treatment of Cancer genitourinary group\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"62\";s:8:\"\u0000*\u0000epage\";s:2:\"71\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"FOSSA\";s:10:\"\u0000*\u0000aufirst\";s:4:\"S. D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:14:\"SLEE, P. H. Th\";i:1;s:9:\"BRAUSI, M\";i:2;s:12:\"HORENBLAS, S\";i:3;s:10:\"HALL, R. R\";i:4;s:18:\"HETHERINGTON, J. W\";i:5;s:11:\"AARONSON, N\";i:6;s:12:\"DE PRIJCK, L\";i:7;s:11:\"COLLETTE, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:226:\"Flutamide versus prednisone in patients with prostate Cancer symptomatically progressing after androgen-ablative therapy : A phase III study of the European Organization for Research and Treatment of Cancer genitourinary group\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2001.19.1.62\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2001.19.1.62\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:226:\"Flutamide versus prednisone in patients with prostate Cancer symptomatically progressing after androgen-ablative therapy : A phase III study of the European Organization for Research and Treatment of Cancer genitourinary group\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"62\";s:8:\"\u0000*\u0000epage\";s:2:\"71\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"FOSSA\";s:10:\"\u0000*\u0000aufirst\";s:4:\"S. D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:14:\"SLEE, P. H. Th\";i:1;s:9:\"BRAUSI, M\";i:2;s:12:\"HORENBLAS, S\";i:3;s:10:\"HALL, R. R\";i:4;s:18:\"HETHERINGTON, J. W\";i:5;s:11:\"AARONSON, N\";i:6;s:12:\"DE PRIJCK, L\";i:7;s:11:\"COLLETTE, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:226:\"Flutamide versus prednisone in patients with prostate Cancer symptomatically progressing after androgen-ablative therapy : A phase III study of the European Organization for Research and Treatment of Cancer genitourinary group\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2001.19.1.62\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:226:\"Flutamide versus prednisone in patients with prostate Cancer symptomatically progressing after androgen-ablative therapy : A phase III study of the European Organization for Research and Treatment of Cancer genitourinary group\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"62\";s:8:\"\u0000*\u0000epage\";s:2:\"71\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"FOSSA\";s:10:\"\u0000*\u0000aufirst\";s:4:\"S. D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:14:\"SLEE, P. H. Th\";i:1;s:9:\"BRAUSI, M\";i:2;s:12:\"HORENBLAS, S\";i:3;s:10:\"HALL, R. R\";i:4;s:18:\"HETHERINGTON, J. W\";i:5;s:11:\"AARONSON, N\";i:6;s:12:\"DE PRIJCK, L\";i:7;s:11:\"COLLETTE, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:226:\"Flutamide versus prednisone in patients with prostate Cancer symptomatically progressing after androgen-ablative therapy : A phase III study of the European Organization for Research and Treatment of Cancer genitourinary group\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2001.19.1.62\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:226:\"Flutamide versus prednisone in patients with prostate Cancer symptomatically progressing after androgen-ablative therapy : A phase III study of the European Organization for Research and Treatment of Cancer genitourinary group\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2001\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:2:\"62\";s:8:\"\u0000*\u0000epage\";s:2:\"71\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"FOSSA\";s:10:\"\u0000*\u0000aufirst\";s:4:\"S. D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:14:\"SLEE, P. H. Th\";i:1;s:9:\"BRAUSI, M\";i:2;s:12:\"HORENBLAS, S\";i:3;s:10:\"HALL, R. R\";i:4;s:18:\"HETHERINGTON, J. W\";i:5;s:11:\"AARONSON, N\";i:6;s:12:\"DE PRIJCK, L\";i:7;s:11:\"COLLETTE, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:226:\"Flutamide versus prednisone in patients with prostate Cancer symptomatically progressing after androgen-ablative therapy : A phase III study of the European Organization for Research and Treatment of Cancer genitourinary group\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
